Pembrolizumab is an immunotherapy medicine used to treat many kinds of cancer, like melanoma and lung cancer. It works by taking the brakes off the immune system so it can find and attack cancer cells. It's given as an infusion into a vein, or as a shot under the skin.
Every report comes from a Lived member, sent anonymously.
Have you tried Keytruda (Pembrolizumab) for Non-Small Cell Lung Cancer?
Pembrolizumab, sold as Keytruda, is a cancer immunotherapy. Rather than attacking cancer cells directly, as chemotherapy does, it helps the body's own immune system recognize and fight the cancer. It belongs to a group of medicines called immune checkpoint inhibitors. It is approved for a long and growing list of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, triple-negative breast cancer, bladder and other urinary tract cancers, kidney cancer, and cancers of the stomach, esophagus, cervix, uterus (endometrium) and ovary. It is also used for some lymphomas, such as classical Hodgkin lymphoma that has come back or not responded to other treatment. Some approvals depend on the tumor's features rather than where it started: for example, colorectal and other solid tumors that are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), meaning the cancer cells cannot properly repair errors in their DNA. How it is used depends on the cancer and its stage. It may be given alone or with chemotherapy or another targeted medicine, for advanced cancer, or before and after surgery to lower the chance of the cancer coming back. Many uses also require a lab test on the tumor, such as a PD-L1 test, which measures a protein some tumors use to switch off immune cells, so having one of these cancers does not by itself mean pembrolizumab is the right option.
The immune system has built-in brakes, called checkpoints, that keep it from attacking healthy tissue. One of these is a protein called PD-1 (programmed death-1) on T cells, the immune cells that can kill infected or abnormal cells. When PD-1 connects with a partner protein called PD-L1 (programmed death-ligand 1), it signals the T cell to stand down. Some cancers produce large amounts of PD-L1, which lets them switch off the T cells that would otherwise attack them. Pembrolizumab is a monoclonal antibody, a lab-made protein that attaches to PD-1 and blocks that connection. With the brake released, T cells can respond to the cancer more strongly. The same release explains its main risk: the more active immune system can also turn on healthy organs.
Keytruda is given in a clinic or infusion center as an infusion into a vein over about 30 minutes. Adults usually receive it every 3 weeks or every 6 weeks, depending on the dose schedule chosen. Children receive a weight-based dose every 3 weeks. When it is combined with chemotherapy or another medicine, the schedule is coordinated with those treatments. Keytruda Qlex is a newer version given as an injection under the skin of the thigh or belly, taking 1 to 2 minutes. It contains an added enzyme that helps the medicine spread under the skin. A health professional gives it, and its doses differ from the infusion, so the two are not swapped dose for dose, although people can switch from one to the other at a scheduled treatment. Qlex is mainly approved for adults and is not approved for the lymphomas that Keytruda treats. How long treatment lasts depends on the reason it is used. For advanced cancer it often continues until the cancer grows or side effects become too much, commonly for up to 2 years. When it is given after surgery, treatment is usually limited to a set course of up to about a year. The care team adjusts the plan by pausing or stopping treatment rather than lowering the dose. Missed appointments should be rescheduled as soon as possible.
Tiredness, muscle or joint pain, rash, itching, diarrhea, fever, cough, decreased appetite, nausea and constipation are among the more common effects when pembrolizumab is used alone. When it is combined with chemotherapy, side effects of the chemotherapy, such as hair loss, nerve tingling and low blood counts, are added. The effects that need the most attention come from the immune system attacking healthy organs. This can inflame the lungs, bowel, liver, kidneys, skin or hormone glands, and less often the heart, nerves, muscles or eyes. These reactions can be serious and occasionally fatal, can affect more than one organ at once, and can start at any time, including months after the last dose. Thyroid problems are among the most common: an underactive thyroid can cause tiredness, weight gain and feeling cold, and it often needs lifelong thyroid hormone pills. Pembrolizumab can also trigger type 1 diabetes, which can come on quickly. Contact the care team right away for new or worsening cough, shortness of breath or chest pain; diarrhea, bloody or black stools, or severe belly pain; yellowing of the skin or eyes, dark urine, or easy bruising; headaches that will not go away, extreme tiredness, dizziness or fainting, or unusual thirst and frequent urination; or blistering or peeling skin and painful mouth sores. Caught early, most of these reactions can be treated with corticosteroids or, for hormone problems, hormone replacement, and treatment may be paused or stopped. Reactions during the infusion or injection, such as chills, flushing or wheezing, are uncommon and are handled by the staff giving it.
Pembrolizumab does not have the long list of drug interactions that many pills do, but the care team should still know about every medicine and supplement, partly because steroids and other immune-suppressing drugs can be used to manage its side effects. Make sure any other doctor who treats you knows you are receiving or recently received immunotherapy, because immune side effects can look like ordinary illnesses. Tell the care team before starting if you have an autoimmune disease such as Crohn's disease, ulcerative colitis or lupus; have had an organ or corneal transplant, which the immune system could reject; have had or may need a stem cell transplant from a donor, since serious complications including graft-versus-host disease have occurred; have had radiation to the chest, which raises the risk of lung inflammation; or have a nerve condition such as myasthenia gravis or Guillain-Barré syndrome. These do not always rule out treatment, but they change the balance of risk and the monitoring plan. Pembrolizumab can harm a developing baby. A pregnancy test is done before starting, and women who could become pregnant should use effective birth control during treatment and for 4 months after the last dose. Breastfeeding is not recommended during treatment or for 4 months afterward. Keytruda Qlex should not be used by anyone who has had an allergic reaction to hyaluronidase, the enzyme it contains.
Treatment visits usually include a check of symptoms and blood tests for liver, kidney and thyroid function, along with blood sugar. Scans are repeated over time to see how the cancer is responding. Responses vary widely. Some people have a lasting response, while others see little benefit, and doctors cannot yet reliably predict who will respond, which is why tumor tests guide many uses. When it is given before or after surgery, the goal is to lower the chance of the cancer returning, so there may be nothing to notice even when it is working. Because immune side effects can appear late, staying alert to new symptoms matters for months after the final dose. Some effects, especially thyroid and other hormone problems, can be permanent and need ongoing treatment even after the cancer treatment ends.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Keytruda (Pembrolizumab), what you've noticed, or ask the community a question.